Literature DB >> 28791626

Fatal ruxolitinib-related JC virus meningitis.

Begoña Ballesta1, Héctor González2, Vicente Martín3, Juan J Ballesta4,5.   

Abstract

We report a possible association between ruxolitinib and JC virus meningitis. A 72-year-old man with myelofibrosis started treatment with ruxolitinib. Fourteen days later, the patient presented to the emergency department with fever and nausea. HIV test was negative. Ruxolitinib was suspended. Symptoms progressed with neck stiffness, cognitive impairment, and motor aphasia. CSF was positive for JC virus. MRI showed nonspecific abnormal findings. Five days after the clinical debut, the patient died. The clinical picture, MRI imaging, and positive JC virus PCR in CSF strongly suggest ruxolitinib-related JC virus meningitis.

Entities:  

Keywords:  JC virus meningitis; Myelofibrosis; Ruxolitinib

Mesh:

Substances:

Year:  2017        PMID: 28791626     DOI: 10.1007/s13365-017-0558-4

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  13 in total

1.  Progressive multifocal leukoencephalopathy associated with ruxolitinib.

Authors:  Rowan Wathes; Simon Moule; Dragana Milojkovic
Journal:  N Engl J Med       Date:  2013-07-11       Impact factor: 91.245

2.  JC virus infection of the brain.

Authors:  A K Bag; J K Curé; P R Chapman; G H Roberson; R Shah
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

3.  JC virus infection is acquired very early in life: evidence from a longitudinal serological study.

Authors:  Francesca Elia; Sonia Villani; Federico Ambrogi; Lucia Signorini; Simone Dallari; Sandro Binda; Valeria Primache; Laura Pellegrinelli; Pasquale Ferrante; Serena Delbue
Journal:  J Neurovirol       Date:  2016-08-18       Impact factor: 2.643

Review 4.  Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.

Authors:  Arturo J Martí-Carvajal; Vidhu Anand; Ivan Solà
Journal:  Cochrane Database Syst Rev       Date:  2015-04-10

Review 5.  Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification.

Authors:  Nicholas Schwab; Tilman Schneider-Hohendorf; Nico Melzer; Gary Cutter; Heinz Wiendl
Journal:  Neurology       Date:  2017-02-22       Impact factor: 9.910

6.  Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis.

Authors:  F Cervantes; J C Hernández-Boluda; N Villamor; A Serra; E Montserrat
Journal:  Eur J Haematol       Date:  2000-08       Impact factor: 2.997

Review 7.  Novel syndromes associated with JC virus infection of neurons and meningeal cells: no longer a gray area.

Authors:  Dhanashri P Miskin; Igor J Koralnik
Journal:  Curr Opin Neurol       Date:  2015-06       Impact factor: 5.710

8.  A fatal case of JC virus meningitis presenting with hydrocephalus in a human immunodeficiency virus-seronegative patient.

Authors:  Shruti P Agnihotri; Christian Wuthrich; Xin Dang; David Nauen; Reza Karimi; Raphael Viscidi; Evelyn Bord; Stephanie Batson; Juan Troncoso; Igor J Koralnik
Journal:  Ann Neurol       Date:  2014-06-20       Impact factor: 10.422

Review 9.  JAKs and STATs in immunity, immunodeficiency, and cancer.

Authors:  John J O'Shea; Steven M Holland; Louis M Staudt
Journal:  N Engl J Med       Date:  2013-01-10       Impact factor: 91.245

10.  JC virus encephalopathy is associated with a novel agnoprotein-deletion JCV variant.

Authors:  Xin Dang; Christian Wüthrich; Jennifer Gordon; Hirofumi Sawa; Igor J Koralnik
Journal:  PLoS One       Date:  2012-04-19       Impact factor: 3.240

View more
  11 in total

1.  JC virus infection of meningeal and choroid plexus cells in patients with progressive multifocal leukoencephalopathy.

Authors:  Sarah M Corbridge; Richard C Rice; Linda A Bean; Christian Wüthrich; Xin Dang; Daniel A Nicholson; Igor J Koralnik
Journal:  J Neurovirol       Date:  2019-04-25       Impact factor: 2.643

2.  Susceptibility of Primary Human Choroid Plexus Epithelial Cells and Meningeal Cells to Infection by JC Virus.

Authors:  Bethany A O'Hara; Gretchen V Gee; Walter J Atwood; Sheila A Haley
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

3.  Persistent polyomavirus-associated nephropathy in a patient with GvHD and treatment with the JAK1/2 inhibitor ruxolitinib.

Authors:  Matthias A Fante; Ernst Holler; Barbara Schmidt; Daniel Wolff; Yvonne Ehrl; Annelie Plentz
Journal:  Bone Marrow Transplant       Date:  2018-10-22       Impact factor: 5.483

Review 4.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

5.  Fatal encephalopathy with wild-type JC virus and ruxolitinib therapy.

Authors:  Lauren Bowen Reoma; Christopher Julius Trindade; Maria Chiara Monaco; Jamie Solis; Marta Garcia Montojo; Phuong Vu; Kory Johnson; Erin Beck; Govind Nair; Omar I Khan; Marta Quezado; Stephen M Hewitt; Daniel S Reich; Richard Childs; Avindra Nath
Journal:  Ann Neurol       Date:  2019-10-16       Impact factor: 11.274

6.  [Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19].

Authors:  H Mei; Y Hu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-03-14

Review 7.  Cryptococcal fungemia and Mycobacterium haemophilum cellulitis in a patient receiving ruxolitinib: a case report and literature review.

Authors:  Naruemit Sayabovorn; Piriyaporn Chongtrakool; Methee Chayakulkeeree
Journal:  BMC Infect Dis       Date:  2021-01-07       Impact factor: 3.090

Review 8.  JAK-STAT Pathway: A Novel Target to Tackle Viral Infections.

Authors:  Ifeanyi Jude Ezeonwumelu; Edurne Garcia-Vidal; Ester Ballana
Journal:  Viruses       Date:  2021-11-27       Impact factor: 5.048

9.  JC virus granule cell neuronopathy associated with Ruxolitinib: A case report and review of the literature.

Authors:  Kentaro Nakayama; Masataka Nakamura; Akiko Konishi; Satoshi Kaneko; Kazuo Nakamichi; Masayuki Saijo; Yusuke Yakushiji; Hirofumi Kusaka
Journal:  eNeurologicalSci       Date:  2020-09-02

Review 10.  Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity.

Authors:  Jérôme Hadjadj; Marie-Louise Frémond; Bénédicte Neven
Journal:  Front Immunol       Date:  2021-09-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.